Journal article icon

Journal article

Preclinical testing of an ATR inhibitor demonstrates improved response to standard therapies for esophageal cancer

Abstract:

Background and Purpose

Esophageal cancer has a persistently low 5-year survival rate and has recently been classified as a cancer of unmet need by Cancer Research UK. Consequently, new approaches to therapy are urgently required. Here, we tested the hypothesis that an ATR inhibitor, VX-970, used in combination with standard therapies for esophageal cancer could improve treatment outcome.

Material and Methods

Using esophageal cancer cell lines we eval...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.radonc.2016.10.023

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
Expand authors...
More from this funder
Funding agency for:
Dobrynin, G
More from this funder
Funding agency for:
Senra, J
More from this funder
Funding agency for:
Hawkins, M
Grant:
MC_PC_12001/2
More from this funder
Funding agency for:
Hammond, E
Expand funders...
Publisher:
Elsevier Publisher's website
Journal:
Radiotherapy and Oncology Journal website
Volume:
121
Issue:
2
Pages:
232-238
Publication date:
2016-11-10
Acceptance date:
2016-10-26
DOI:
ISSN:
0167-8140
Source identifiers:
657584
Keywords:
Pubs id:
pubs:657584
UUID:
uuid:48b82627-9930-4031-8c49-3b86a535ac57
Local pid:
pubs:657584
Deposit date:
2016-11-09

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP